121 related articles for article (PubMed ID: 12386267)
21. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
Funahashi H; Tanaka Y; Imai T; Wada M; Tsukamura K; Hayakawa Y; Matsuura N; Kikumori T; Oiwa M; Tominaga Y; Takagi H
J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men.
Brandi L; Egfjord M; Olgaard K
Nephrol Dial Transplant; 2002 May; 17(5):829-42. PubMed ID: 11981071
[TBL] [Abstract][Full Text] [Related]
24. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
[TBL] [Abstract][Full Text] [Related]
25. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
Kinugasa E; Akizawa T; Takahashi J; Nabeshima K; Ogata H; Nakayama F; Ideura T
Nephrol Dial Transplant; 2002; 17 Suppl 10():20-7. PubMed ID: 12386265
[TBL] [Abstract][Full Text] [Related]
26. 'Pulse' oral calcitriol in uraemic patients: rapid modification of parathyroid response to calcium.
Kwan JT; Almond MK; Beer JC; Noonan K; Evans SJ; Cunningham J
Nephrol Dial Transplant; 1992; 7(8):829-34. PubMed ID: 1325616
[TBL] [Abstract][Full Text] [Related]
27. Once weekly intravenous calcitriol suppresses hyperparathyroidism in hemodialysis patients.
Stim JA; Lowe J; Arruda JA; Dunea G
ASAIO J; 1995; 41(3):M693-8. PubMed ID: 8573894
[TBL] [Abstract][Full Text] [Related]
28. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
29. Chronopharmacology of oxacalcitriol in 5/6 nephrectomized rats.
Tsuruoka S; Nishiki K; Wakaumi M; Yamamoto H; Ando H; Ning W; Fujimura A
Life Sci; 2004 Jul; 75(7):809-22. PubMed ID: 15183074
[TBL] [Abstract][Full Text] [Related]
30. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
Hirata M; Katsumata K; Masaki T; Koike N; Endo K; Tsunemi K; Ohkawa H; Kurokawa K; Fukagawa M
Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
[TBL] [Abstract][Full Text] [Related]
31. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
[TBL] [Abstract][Full Text] [Related]
32. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
Murakami K; Miyachi H; Watanabe A; Kawamura N; Fujii M; Koide S; Murase M; Kushimoto H; Hasegawa M; Tomita M; Hiki Y; Sugiyama S
Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
[TBL] [Abstract][Full Text] [Related]
33. Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale.
Gallieni M; Brancaccio D; Antonucci F; Bellinghieri G; Carpani P; Cozzolino M; D'Agostino F; Del Mastro G; Mallamace A; Memoli B
Clin Nephrol; 2000 Mar; 53(3):188-93. PubMed ID: 10749297
[TBL] [Abstract][Full Text] [Related]
34. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.
Slatopolsky E; Finch J; Denda M; Ritter C; Zhong M; Dusso A; MacDonald PN; Brown AJ
J Clin Invest; 1996 Jun; 97(11):2534-40. PubMed ID: 8647946
[TBL] [Abstract][Full Text] [Related]
35. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Nishii Y; Abe J; Mori T; Brown AJ; Dusso AS; Finch J; Lopez-Hilker S; Morrissey J; Slatopolsky E
Contrib Nephrol; 1991; 91():123-8. PubMed ID: 1800003
[TBL] [Abstract][Full Text] [Related]
36. Intravenous calcitriol lowers serum calcium concentrations in uraemic patients with severe hyperparathyroidism and hypercalcaemia.
Hamdy NA; Brown CB; Kanis JA
Nephrol Dial Transplant; 1989; 4(6):545-8. PubMed ID: 2507976
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial.
Moe SM; Kraus MA; Gassensmith CM; Fineberg NS; Gannon FH; Peacock M
Nephrol Dial Transplant; 1998 May; 13(5):1234-41. PubMed ID: 9623560
[TBL] [Abstract][Full Text] [Related]
38. In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [(3)H]1,25-dihydroxy-22-oxavitamin D(3) compared with [(3)H]1,25-dihydroxyvitamin D(3), determined by micro-autoradiography.
Koike N; Hayakawa N; Tokuda K; Nishimiya K; Saito K; Stumpf WE
Nephrol Dial Transplant; 2002; 17 Suppl 10():53-7. PubMed ID: 12386270
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
40. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
Zella JB; Plum LA; Plowchalk DR; Potochoiba M; Clagett-Dame M; DeLuca HF
Am J Nephrol; 2014; 39(6):476-83. PubMed ID: 24854296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
